Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia

KRZYSZTOF GIANNOPoulos1,2, MICHAEL SCHMitt1, MALGORZATA KOWAL2, PAULINA WlASIUK2, AGNIESZKA BOJARSKA-JUNAK3, JINFEI CHEN1, JACEK ROLINSKI3 and ANNA DMOSZYNSKA2

1Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany; Departments of
2Hematology and 3Clinical Immunology, Medical University of Lublin, 20-950 Lublin, Poland

Received April 9, 2008; Accepted May 8, 2008

DOI: 10.3892/or_00000059

Abstract. The status of the immune system of patients with B-cell chronic lymphocytic leukemia (B-CLL) is not yet sufficiently characterized. Clinically, B-CLL patients present immunodeficiency increasing along with disease progression and signs of autoimmune. In the current study, we evaluated the expression of FOXP3 in CD4+CD25hi T regulatory lymphocytes (Treg) and their influence on immune response against tumor and viral antigens in the complex system of peripheral blood mononuclear cells. In 80 B-CLL patients, the frequency of Treg (CD4+CD25hi FOXP3+) cells was significantly higher in B-CLL patients when compared to healthy volunteers (HV) and increased with the progression of the disease (median: 8.24% in stage A, 11.24% in stage B and 12.57% in stage C according to the Binet classification). The frequency of Treg showed no correlation with prognostic markers such as ZAP-70, CD38 and HLA-G. Notably, Treg frequency correlated with serum levels of TNF (r=0.45, p=0.001). T-cell immune responses against epitopes derived from the tumor-associated antigens survivin, fibromodulin and RHAMM as well as from the influenza matrix protein were evaluated. Functionally, higher frequencies of Treg correlated with decreased T-cell responses against viral and tumor antigens. In conclusion, we detected enhanced frequencies of CD4+CD25hi T regulatory cells (Treg) in B-CLL and their influence on immune response against viral and tumor antigens. Several immunosuppressive mechanisms allow CLL cells to escape from immunosurveillance. Recently, enhanced frequencies of CD4+CD25hi T regulatory cells (Treg) in B-CLL were reported by Beyer et al. (8). Apart from CD4+CD25hi T cells, other immunomodulatory factors such as cytokines IL-10 and TGF-β may suppress immune responses (9,10). Defects of immune response might be induced by a direct cell-cell contact suggesting the immunosuppressive role of the B-CLL cell itself that might be mediated by the expression of the non-classic human leukocyte antigen (HLA)-G protein (11). HLA-G released in its soluble (sHLA-G) form may also inhibit immune responses against TAA since sHLA-G inhibits the function of T as well as NK cells leading to tumor progression (12).

Tumor progression promoted by an elevated frequency of Treg was also reported for other carcinomas (13,14). The addition of CD4+CD25hi cells to a mixed lymphocyte reaction (MLR) resulted in a decreased antigen recognition by T cells (8,15), which clearly proved the potency of Treg in suppressing T-cell responses (8,16). The single addition of Treg to an immunosuppressive assay was able to confirm their inhibitory potential. However, little is known about the role of Treg in the more complex system of peripheral blood (PB). Treg are considered as key immunomodulatory cells of the immune system. The forkhead family transcription factor, FOXP3, is critically important for the development and function of Treg (17). In this study, the expression of FOXP3 was assessed in CD4+ cells from the PB of patients with B-CLL. Furthermore, we wanted to characterize the role of Treg in the specific T-cell response against tumor and viral antigens in a complex system containing a whole population of B-cell chronic lymphocytic leukemia (B-CLL) patients present immunodeficiency, along with signs of autoimmunity (3). Several studies have aimed to characterize the immunity of B-CLL, however, results were ambiguous and difficult to interpret especially towards active immunotherapy for those patients (4). The graft vs. leukemia effect (5) as well as the ‘spontaneous’ remissions associated with an increased immunity against viral antigens (6) suggest that CLL cells may be targeted by a T cell-mediated immune response. Naturally occurring tumor-reactive T cells were found in some B-CLL patients (7). During disease progression, patients displayed signs of immunosuppression resulting in an impaired immune response against tumor-associated antigens (TAA) as well as against viral and bacterial antigens. Several immunosuppressive mechanisms allow CLL cells to escape from immunosurveillance. Recently, enhanced frequencies of CD4+CD25hi T regulatory cells (Treg) in B-CLL were reported by Beyer et al. (8). Apart from CD4+CD25hi T cells, other immunomodulatory factors such as cytokines IL-10 and TGF-β may suppress immune responses (9,10). Defects of immune response might be induced by a direct cell-cell contact suggesting the immunosuppressive role of the B-CLL cell itself that might be mediated by the expression of the non-classic human leukocyte antigen (HLA)-G protein (11). HLA-G released in its soluble (sHLA-G) form may also inhibit immune responses against TAA since sHLA-G inhibits the function of T as well as NK cells leading to tumor progression (12).

Introduction

The immune status of patients with B-cell chronic lymphocytic leukemia (B-CLL) is poorly characterized (1,2). Clinically,
mononuclear cells of B-CLL patients. We therefore evaluated T-cell-mediated immune responses against HLA-A2-restricted epitopes of survivin, a member of the antiapoptotic protein family as well as recently defined epitopes derived from fibromodulin and RHAMM (18-20).

Recently, Valencia et al (21) reported that TNF inhibited the suppressive function of Treg in patients with rheumatoid arthritis (RA). The exact role of TNF in the regulation of Treg function remains to be elucidated. Therefore, we assessed the expression of Treg by TNF as well as TNF receptors, since it was shown that elevated levels of TNF were associated with progressive disease in B-CLL patients. Moreover, based on results obtained in RA, one might speculate on a decreased Treg frequency as well as the function in advanced stage CLL patients with elevated TNF levels (22).

Materials and methods

Cell samples. Samples were taken from 80 previously untreated B-CLL patients admitted to the Department of Hemato-oncology, Medical University of Lublin. This study was approved by the Local Ethics Committee (KE-0254/178/2006). The peripheral blood samples were taken from 10 healthy volunteers (HVs; age range: 25-75 years, mean: 56 years; 6 male and 4 female). Informed consent was obtained from all patients and HVs with respect to the use of their blood for scientific purposes. Thirty-three patients were classified in stage A, 28 in B and 19 in C according to the Binet classification (mean age: 63 years, range: 37-93). The clinical characteristics of the patients are summarized in Table I. No autoimmune effects such as autoimmune hemolytic anemia or autoimmune thrombocytopenia were observed in these patients.

Cell isolation. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density gradient centrifugation. The viability of obtained PBMC was always >95%, as determined by trypan blue staining. Viable cells were quantified in a Neubauer chamber (Zeiss, Oberkochen, Germany) and stored in liquid nitrogen for FACS analysis and functional assays.

Peptides. Based on our previous studies (18,23), the RHAMM-derived HLA-A2 restricted the CD8+ T cell epitope R3 (pos. 165-173; ILSLELMKL) and was chosen as an immunogenic peptide in B-CLL. Fibromodulin- and survivin-derived peptides FMOD (pos. 250-259; YMEHNNVYTV) and SUR (pos. 97-106 ELTLGEFLKL) were selected based on published data (19,20). As a viral peptide, the influenza matrix protein (IMP)-derived peptide (GILGFVFTL) was used. Peptides were synthesized by Thermo Electron Corporation (Ulm, Germany) with a minimum of 95% purity as measured by high performance liquid chromatography (HLPC). All peptides were HLA-A2 restricted.

Mixed lymphocyte peptide culture (MLPC) and interferon (IFN)-γ ELISpot assay. PBMC from HLA-A2-positive B-CLL patients were thawed with a yield of >95% viable cells and subsequently left for 24 h of resting period in the culture medium containing RPMI-1640, supplemented with a 10% FCS serum (Biochrom AG, Berlin, Germany). The following day, cells were counted, placed in a 6-well plate and pulsed with R3, FMOD, IMP or SUR peptides at a concentration of 20 μg/ml, or without peptide as a negative control, respectively. The MLPC was supplemented with 10 U/ml IL-2 (human interleukin-2, Sigma-Aldrich, Munich, Germany) and 20 ng/ml IL-7 (recombinant, human interleukin-7, Strathmann Biotec AG, Hamburg, Germany) on day +1. On day +7 of MLPC, cells were harvested and evaluated for their specific cytotoxicity in an ELISpot assay with IMP, R3, FMOD and SUR peptides, with the unspecific positive control pokeweed mitogen (PWM) (Sigma-Aldrich) or without a peptide, as a negative control as described in detail earlier (18). ELISpot assays were performed as described elsewhere (24) to determine the specific secretion of IFN-γ against R3, FMOD, SUR or IMP-positive target cells according to the manufacturer's instructions (Mabtech AG, Nacka, Sweden). ELISpot assays were performed under the conditions recommended by the Cancer Immunotherapy (C-IMT) Monitoring Panel to which our institutions contributed (25).

FACS analysis of regulatory T cells (Treg). PBMC from B-CLL patients were thawed with RPMI-1640 containing DNA-ase (Sigma-Aldrich) with a yield of >95% viable cells.

### Table I. Basic characteristics of 80 B-CLL patients.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>50</td>
</tr>
<tr>
<td>Female</td>
<td>30</td>
</tr>
<tr>
<td>Age</td>
<td></td>
</tr>
<tr>
<td>40-49</td>
<td>5</td>
</tr>
<tr>
<td>50-59</td>
<td>23</td>
</tr>
<tr>
<td>60-69</td>
<td>25</td>
</tr>
<tr>
<td>70-79</td>
<td>26</td>
</tr>
<tr>
<td>&gt;80</td>
<td>1</td>
</tr>
<tr>
<td>Binet stage</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>33</td>
</tr>
<tr>
<td>B</td>
<td>28</td>
</tr>
<tr>
<td>C</td>
<td>19</td>
</tr>
<tr>
<td>Lymphocytosis (G/L)</td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>16</td>
</tr>
<tr>
<td>20-50</td>
<td>25</td>
</tr>
<tr>
<td>&gt;50</td>
<td>39</td>
</tr>
<tr>
<td>ZAP-70 (cut-off 20%)</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>43</td>
</tr>
<tr>
<td>Negative</td>
<td>46</td>
</tr>
<tr>
<td>Not available</td>
<td>3</td>
</tr>
<tr>
<td>CD38 (cut-off 30%)</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>58</td>
</tr>
<tr>
<td>Negative</td>
<td>16</td>
</tr>
<tr>
<td>Not available</td>
<td>6</td>
</tr>
</tbody>
</table>
Thereafter, cells were washed twice in PBS containing 2% FCS (Biochrom AG) and were counted. The staining of the surface antigens CD4, CD8 and CD25 was performed after the incubation of $1\times10^6$ cells with antibodies, according to the manufacturer’s protocols (BD Biosciences, Mannheim, Germany). Cells were then permeabilized, blocked with rat serum and stained with an anti-FOXP3 rat monoclonal antibody according to manufacturer’s protocols (eBioscienes, San Diego, CA, USA). After the intracellular staining, cells were washed twice and analyzed by flow cytometry for the expression of FOXP3 and CD25 on CD4+ cells. At least 100,000 cells were collected and analyzed.

**Evaluation of TNF receptor 1 (TNF R1) and R2 expression.**
Expression of TNF R1 and R2 was performed by FACS analysis, as described previously in detail (26).

**Figure 1.** Four color-staining of $\text{CD4}^+\text{CD25}^+\text{FOXP3}^+$ T regulatory cells in B-CLL patients. The lymphocyte subpopulation was gated (R1) based on forward vs. side scatter (FSC/SSC) characteristics (A). Compared to the isotype (B) and FMO (Fluorescence Minus One) (C) controls, the intracellular expression of FOXP3 was evaluated in CD4+ T cells (D). This gating strategy was compared to the expression of CD4+CD25+ T cells (E). All cells gated as CD4+FOXP3+ were CD25+.

**Figure 2.** The frequency of Treg in B-CLL increases with the stage of the disease. The median frequency of Treg was compared between groups of B-CLL patients at different stages (according to the Binet classification).

---

**Results**

**The frequency of Treg increased with the stage of the disease.**
In B-CLL patients, we identified the subpopulation of CD4+CD25+FOXP3+ T cells as regulatory T cells (Treg) (Fig. 1). The median frequency of Treg was significantly higher in B-CLL patients when compared to HV (10.59 vs. 1.9%, $p=0.0001$). The progressive increase of Treg was noted in the advanced stages of the disease. A median percentage of Treg for CLL patients in stage A was 8.24%, 11.24% in stage B and 12.57% in stage C according to the Binet classification (Fig. 2).

**Correlation of Treg with age and prognostic factors.**
No correlation between the percentage of Treg and ZAP-70 status was observed. A tendency to higher frequencies in ZAP-70 negative patients was noted 11.1 vs. 8.85% ($p=0.32$). Similarly, there was a tendency for higher percentages of Treg in patients...
who were CD38 (-) (10.3 vs. 9.96% p=0.88). No correlation of Treg frequency and lymphocyte count or age of patients was noted (r²=0.079, p=0.029).

Treg increased with respect to TNF serum levels. Higher frequencies of Treg were observed in CLL patients with higher levels of TNF serum (r²=0.45, p=0.001, n=20). No correlation between the frequency of Treg and the expression of TNFR1 (n=40) or TNFR2 (n=40) was observed.

Treg correlated inversely with serum levels of HLA-G. An inverse correlation between the frequency of Treg and the serum level of soluble HLA-G (sHLA-G) was observed (r²=-0.37, p<0.03, n=36, Fig. 3). The surface expression of HLA-G molecules in CD5⁺CD19⁺ CLL cells tended to be lower in patients with higher percentages of Treg (r²=-0.23, p=NS, n=20).

Correlation of Treg frequencies and the T-cell responses in ELISpot assays. Higher frequencies of Treg correlated with a significantly lower secretion of IFN-γ against tumor and viral antigens (Fig. 4, cut off = 10.5%, calculated in the median frequency of Treg). Patients with lower frequencies of Treg displayed preserved T-cell function. The results from an ELISpot assay of a CLL patient is shown in Fig. 5.

Discussion

The human immune system develop mechanisms, which eliminate pathogens as well as protect the organism from self-destruction. In the control of immunosurveillance, the so-called ‘natural’ regulatory T cells (Treg) play a pivotal role. However, the definition of ‘natural’ Treg is a matter of debate. Markers such as CD25, GITR and CD62L were tested by FACS analysis, although only the intracellular staining of FOXP3, the specific transcription factor of Treg, defines a distinct population of Treg (Fig. 1). In B-CLL, we identified a population of Treg (CD4⁺CD25⁺FOXP3⁺) at frequencies increasing with the stage of the disease (Fig. 2). Moreover, these Treg were functionally able to abrogate T cell responses against TAA and viral antigens (Fig. 4). Several studies have shown the inhibitory properties of Treg in immunosuppressive assays, where a single agent was added to inhibit the immune effect of a mixed lymphocyte reaction (8,15,16). In this study, we showed for the first time that in a complex system of peripheral blood mononuclear cells Treg played a crucial role in the modulation of the immune response against tumor and viral antigens, which underlines the clinically well known immunodeficient status of advanced B-CLL patients through the excess of Treg.

Previously, Amiot et al (27) found that an increased mRNA level of HLA-G mostly resulted in increased serum
levels of soluble HLA-G (sHLA-G), though in a hardly increased expression of HLA-G molecules on the cell surface. In the current study, we observed no correlation between Treg and the expression of surface HLA-G. Notably, an inverse correlation between sHLA-G and Treg was found. Amiot et al (27) reported that increased levels of soluble HLA-G in B-CLL patients might favor the progression of the disease by the inhibition of the T-cell function (12). The results of this study suggest that Treg represent a major mechanism, which is responsible for immunosuppression when compared with HLA-G since T-cell responses in the complex system of PBMC rely on the frequency of Treg, though not HLA-G.

We evaluated Treg frequency in CLL patients with a different prognosis since the increased Treg frequency may represent the main immune mechanism responsible for disease progression in CLL. It is noteworthy that CLL patients with an unfavorable prognosis showed slightly lower percentages of Treg. Treg frequency correlated neither with the expression of ZAP-70 nor with the expression of CD38. Moreover, no correlation of Treg frequency with HLA-G expression was found. HLA-G was reported as a surrogate prognostic marker in B-CLL, superior to ZAP-70 as well as CD38 (11).

The definition of TAA-derived immunogenic epitopes represents a cornerstone for peptide-based immunotherapies. With respect to design, the novel peptide vaccination trials in B-CLL, there is a fervent need to define and add some components which might inhibit Treg in order to induce a T-cell-mediated rejection of CLL cells. However, it is still unclear which factor promotes Treg proliferation.

Elevated levels of TNF were associated with progressive disease in patients with B-CLL and increased with the stage of the disease (22). Here, a correlation between the percentages of Treg and TNF serum levels was observed. This might suggest a promotion of Treg through TNF. Patients with an increased frequency of Treg and elevated levels of TNF displayed an impaired responsiveness against tumor and viral antigens. However, no correlation to the expression of TNF receptors was found. Conversely, TNF was reported to down-regulate the suppressive function of Treg (21). Elevated serum concentrations of TNF are present in various pre-neoplastic and malignant diseases, when compared with serum TNF levels detected in healthy individuals (28). An increased number of Treg was also reported in several malignancies. Possibly, increased TNF levels promote Treg proliferation. Nonetheless, the results of our study suggest that TNF is unable to block the suppressive activity of Treg in B-CLL. Anti-TNF treatment of RA patients with infliximab up-regulated the function of Treg (21). We reported earlier on a specific decrease in the Treg number in B-CLL patients treated with thalidomide, which therapeutic anti-TNF effect is known (29). The ambiguous effect of TNF in RA and CLL patients suggests that several other mechanisms are involved in the regulation of Treg function.

In summary, an increased expression of FOXP3+ Treg in B-CLL patients was found. The percentage of Treg increased along with the stage of the disease. Increased frequencies of Treg were functionally able to inhibit T-cell responses against TAA and viral antigens. These functional studies underline the pivotal role of Treg in the restriction of T-cell responses in the peripheral blood from B-CLL patients.

Acknowledgements

This study was supported by grants from the Polish Scientific Committee KBN N40203431/1138 and N40210732/3496 as well as from the Else Kröner-Fresenius-Foundation A85/06. Krzysztof Giannopoulos was supported by a generous scholarship from the Foundation for Polish Science.
References


